Anika Therapeutics Inc (ANIK) Stock Price

ANIKStock

$21.40+121.14%52W

Market Cap$286.40M

P/E—

PEG Ratio5.59

Div yield—

Beta0.21

ANIK Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)91.61%

Price vs S&P 500 (4W)37.81%

PEG Ratio5.59

VGM Score49.97

P/CF (Annual)25.57x

Book Value / Share (Quarterly)$10.26

P/TBV (Annual)0.98x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-10.28%

Cash Flow / Share (Quarterly)$0.04

Price vs S&P 500 (YTD)110.10%

Gross Margin (TTM)62.16%

Net Profit Margin (TTM)-3.14%

EPS (TTM)$-0.27

10-Day Avg Trading Volume0.13M

EPS Excl Extra (TTM)$-0.27

Revenue Growth (5Y)-2.87%

EPS (Annual)$-0.76

ROI (Annual)-7.58%

Gross Margin (Annual)56.56%

Net Profit Margin (5Y Avg)-22.61%

Cash / Share (Quarterly)$2.87

Revenue Growth QoQ (YoY)15.56%

ROA (Last FY)-5.72%

Revenue Growth TTM (YoY)-2.50%

EBITD / Share (TTM)$0.04

ROE (5Y Avg)-17.39%

Operating Margin (TTM)-4.24%

Cash Flow / Share (Annual)$0.31

P/B Ratio2.08x

P/B Ratio (Quarterly)1.42x

Net Income / Employee (Annual)$-46,300

EV / Revenue (TTM)2.05x

Net Interest Coverage (TTM)13.00x

ROA (TTM)-2.04%

EV / EBITDA (TTM)495.43x

EPS Incl Extra (Annual)$-0.76

Current Ratio (Annual)4.72x

Quick Ratio (Quarterly)3.05x

3-Month Avg Trading Volume0.10M

52-Week Price Return121.14%

EV / Free Cash Flow (Annual)56.79x

Revenue / Employee (TTM)$513,400

Tangible BV / Share (Quarterly)$10.13

P/S Ratio (Annual)2.54x

Asset Turnover (Annual)0.59x

52-Week High$22.88

Operating Margin (5Y Avg)-4.84%

EPS Excl Extra (Annual)$-0.76

CapEx CAGR (5Y)33.17%

Tangible BV CAGR (5Y)-4.78%

26-Week Price Return102.85%

Quick Ratio (Annual)3.71x

13-Week Price Return42.08%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.48x

Enterprise Value$247.72M

Revenue / Share Growth (5Y)-3.06%

Asset Turnover (TTM)0.65x

Book Value / Share Growth (5Y)-11.52%

Revenue / Employee (Annual)$480,100

Inventory Turnover (Annual)2.30x

Pretax Margin (Annual)-8.25%

Cash / Share (Annual)$4.14

3-Month Return Std Dev48.02%

Gross Margin (5Y Avg)57.20%

Net Income / Employee (TTM)$-16,100

EBITDA CAGR (5Y)-46.37%

EBITDA Interim CAGR (5Y)-18.86%

ROE (Last FY)-7.58%

Net Interest Coverage (Annual)-7.33x

EPS Basic Excl Extra (Annual)$-0.76

P/FCF (TTM)31.89x

Receivables Turnover (TTM)4.55x

EV / Free Cash Flow (TTM)440.78x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.27

Receivables Turnover (Annual)4.77x

ROI (TTM)-2.70%

P/S Ratio (TTM)2.37x

Pretax Margin (5Y Avg)-3.80%

Revenue / Share (Annual)$7.87

Tangible BV / Share (Annual)$10.21

Forward P/E68.29x

Free OCF CAGR (5Y)-17.54%

Price vs S&P 500 (52W)102.83%

Year-to-Date Return122.06%

5-Day Price Return-1.07%

EPS Normalized (Annual)$-0.76

ROA (5Y Avg)-13.43%

Net Profit Margin (Annual)-9.64%

Month-to-Date Return10.68%

Cash Flow / Share (TTM)$-0.69

EBITD / Share (Annual)$-0.40

Operating Margin (Annual)-9.80%

LT Debt / Equity (Annual)0.07x

P/CF (TTM)47.87x

ROI (5Y Avg)-17.39%

LT Debt / Equity (Quarterly)0.09x

EPS Basic Excl Extra (TTM)$-0.27

P/TBV (Quarterly)1.44x

P/B Ratio (Annual)0.97x

Inventory Turnover (TTM)2.01x

Pretax Margin (TTM)-2.41%

Book Value / Share (Annual)$10.33

Price vs S&P 500 (13W)39.28%

Beta0.21x

P/FCF (Annual)65.60x

Revenue / Share (TTM)$8.80

ROE (TTM)-2.70%

52-Week Low$8.37

vGradeC

gGradeD

mGradeA

vgmGradeC

ANIK Earnings Surprise History

Q2 25-0.13est. -0.13

Q3 250.04est. 0.02

Q4 250.31est. 0.02

Q1 260.27est. 0.00

Q2 260.42est. 0.03

ANIK Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.25

Industry Peers — Surgical & Medical Instruments(140)

Symbol	Value Score	Growth Score	Momentum Score	Price
ANIKAnika Therapeutics Inc	C	D	A	$21.40
SYKStryker Corporation	C	B	C	$330.59
MMM3M Company	C	D	B	$179.37
BSXBoston Scientific Corp.	C	B	D	$49.86
BDXBecton, Dickinson and Co.	B	D	B	$189.78
MDLNMedline Inc. Class A common stock	C	D	C	$35.64
RMDResMed Inc.	C	B	C	$236.59
DXCMDexCom, Inc.	D	B	B	$89.16
WSTWest Pharmaceutical Services, Inc.	D	C	B	$348.48
SOLVSolventum Corporation	C	C	B	$91.61
BAXBaxter International Inc.	B	D	B	$26.29
PENPenumbra, Inc.	D	C	C	$324.37
GMEDGLOBUS MEDICAL INC	B	B	C	$82.96
GKOSGlaukos Corporation	F	A	A	$181.39
PODDInsulet Corporation	C	A	D	$143.05
STVNStevanato Group S.p.A.	D	C	B	$22.70
TFXTeleflex Incorporated	B	F	B	$140.18
MMSIMerit Medical Systems Inc	C	B	B	$91.09
MMEDMiniMed Group, Inc. Common Stock	—	—	A	$18.92
HAEHaemonetics Corporation	C	C	A	$108.32
ICUIICU Medical Inc	C	D	B	$182.24
HTFLHeartflow, Inc. Common Stock	—	A	A	$49.89
IRTCiRhythm Holdings, Inc. Common Stock	F	A	C	$123.09
PLSEPulse Biosciences, Inc Common Stock (DE)	F	—	A	$49.00
ATRCAtriCure, Inc.	D	B	A	$48.68
UFPTUFP Technologies Inc	C	B	B	$304.21
NVCRNovoCure Limited Ordinary Shares	D	C	C	$17.62
LMATLeMaitre Vascular, Inc.	C	B	D	$78.97
INSPInspire Medical Systems, Inc.	B	B	B	$61.07
KMTSKestra Medical Technologies, Ltd. Common Stock	F	A	B	$26.92
TNDMTandem Diabetes Care, Inc.	D	C	B	$21.58
ATECAlphatec Holdings, Inc.	D	B	C	$9.33
DRTSAlpha Tau Medical Ltd. Ordinary Shares	—	—	A	$14.70
IARTIntegra LifeSciences Holdings	B	D	C	$16.79
AORTArtivion, Inc.	C	C	C	$26.38
PRCTPROCEPT BioRobotics Corporation Common Stock	C	A	D	$21.60
IRMDiRadimed Corporation	D	B	C	$87.87
BVSBioventus Inc. Class A Common Stock	B	C	A	$14.08
SGPSpyGlass Pharma, Inc. Common Stock	—	—	B	$26.60
SIBNSI-BONE, Inc. Common Stock	D	B	B	$19.54
BBNXBeta Bionics, Inc. Common Stock	D	A	A	$19.34
SSIISS Innovations International Inc. Common Stock	F	A	D	$3.55
ANGOAngioDynamics, Inc.	C	D	B	$15.95
KIDSOrthoPediatrics Corp. Common Stock	C	B	B	$24.50
MDXGMiMedx Group, Inc	C	D	C	$4.34
DCTHDelcath Systems Inc	D	B	A	$16.92
BWAYBrainsway Ltd. American Depositary Shares	F	A	C	$14.43
CERSCerus Corp	D	C	B	$2.72
TCMDTactile Systems Technology, Inc.	B	B	C	$23.58
CLPTClearPoint Neuro, Inc. Common Stock	F	A	B	$16.96
NPCENeuropace, Inc. Common Stock	D	C	C	$14.16

About Anika Therapeutics Inc

Anika Therapeutics develops osteoarthritis pain management solutions using proprietary hyaluronic acid technology. The company's principal products—Orthovisc, Monovisc, and Cingal—are office-administered viscosupplement products marketed exclusively in the U.S. by Johnson & Johnson MedTech. Primary revenue is derived from the U.S. market, with additional contributions from OEM licensing and international operations.